SCHEMBL6506775

SCHEMBL6506775

CC(=O)c1ccc(NC2=C(Cl)C(=O)c3ccccc3C2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN6 P29350 1/20 1.00
MAPT P10636 13/20 0.76
HTT P42858 10/20 0.76
RAB9A P51151 9/20 0.76
NPSR1 Q6W5P4 8/20 0.76
KMT2A Q03164 8/20 0.76
MAPK1 P28482 8/20 0.76
NPC1 O15118 5/20 0.76
L3MBTL1 Q9Y468 5/20 0.76
CDC25A P30304 4/20 0.76
CDC25B P30305 3/20 0.76
HK1 P19367 1/20 0.76
CDC25C P30307 1/20 0.76
HKDC1 Q2TB90 1/20 0.76
ALDH1A1 P00352 6/20 0.74
ATM Q13315 4/20 0.74
MEN1 O00255 7/20 0.68
GAA P10253 4/20 0.68
MITF O75030 3/20 0.68
LMNA P02545 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31612179 1.00 PTPN6 (1.00) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL6869616 0.83 PTPN6 (0.70) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL12283174 0.81 CDC25B (0.76) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL4868219 0.81 MAPT (1.00) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL4873496 0.81 MAPT (1.00) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL32664539 0.80 MAPT (0.79) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL18457363 0.80 PTPN6 (0.67) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL6506683 0.80 MAPT (1.00) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL29633261 0.80 MAPT (1.00) PTPN6MAPTHTTRAB9ANPSR1
SCHEMBL21779251 0.79 HSP90AA1 (0.76) PTPN6MAPTHTTRAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148676-A1 COMBINATION THERAPY WITH PD-1 SIGNAL INHIBITOR KYOTO UNIVERSITY (JP) 2024-05-09 US claimed
EP-4299075-A1 COMBINATION THERAPY WITH PD-1 SIGNAL INHIBITOR Kyoto University (JP) 2024-01-03 EP claimed
US-20240148676-A1 COMBINATION THERAPY WITH PD-1 SIGNAL INHIBITOR KYOTO UNIVERSITY (JP) 2024-05-09 US disclosed
EP-4299075-A1 COMBINATION THERAPY WITH PD-1 SIGNAL INHIBITOR Kyoto University (JP) 2024-01-03 EP disclosed
WO-2018231322-A1 B CELL DISORDER CLASSIFICATION AND SUSCEPTIBITY TO INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-12-20 WO disclosed
US-9272993-B2 Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2016-03-01 US disclosed
US-20140213627-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2014-07-31 US disclosed
US-20050032794-A1 Diamine derivatives of quinone and uses thereof CLINICAL DATA, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213627-A1 NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS APP, PSEN1, PSEN2 PTPN6 3755/4885MAPT 14/4885HTT 13/4885
US-20050032794-A1 Diamine derivatives of quinone and uses thereof NQO1, DPYD, NQO2 PTPN6 3397/4885MAPT 3849/4885HTT 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.